Michel Vounatsos (Credit: World Economic Forum/Valeriano Di Domenico)
March 8, 2022 09:44 AM ESTUpdated March 11, 02:56 AM
Bioregnum

‘We would have no choice’: Bio­gen CEO Vounatsos isn’t about to let go of the bud­get axe — un­less they break that los­ing streak

Bio­gen CEO Michel Vounatsos is bet­ting on suc­cess. But he’s keep­ing one hand firm­ly on the bud­get axe in case the cards stay cold. And …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE
ENDPOINTS CAREERS

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

Why did Eli Lil­ly ask a pa­tient on a com­pound­ed GLP-1 drug for their med­ical in­for­ma­tion?

FDA OKs the first-ever self-ad­min­is­tered vac­cine, for flu

The drug lob­by's law­suit against the IRA finds a sign of life af­ter ap­peals court rul­ing

Biotech VC firm out­lines plans for $100M fund

FTC to sue ma­jor PBMs over in­sulin re­bates, claim­ing they in­flat­ed pa­tient cost

sponsored

Break­ing down si­los with a new quan­ti­ta­tive ap­proach to drug de­vel­op­ment

A service from the Financial Times